Drug Trial Radar · NCT06224907
Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A
Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
6
Planned (sponsor's estimate)
Start
Dec 25, 2023
Primary completion
Apr 16, 2025
Study completion Mar 2029
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- Jan 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase III clinical study will evaluate the safety and effectiveness of valoctocogene roxaparvovec in Japanese patients with severe hemophilia A.
Conditions
- Hemophilia A
Interventions
Valoctocogene roxaparvovecBiological
Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Severe Hemophilia A
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in the human coagulation factor VIII (hFVIII) activity, as measured by chromogenic substrate assay, during Weeks 49 to 52 post BMN 270 infusion from Baseline.Time frame: 52 Weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Asahikawa Medical University Hospital
Hokkaido, Asahikawa, Japan
Saitama Medical University Hospital
Saitama, Iruma-gun, Japan
Nagoya University Hospital
Aichi, Nagoya, Japan
Tokyo Medical University Hospital
Tokyo, Shinjuku-ku, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.